VISEN Pharma Keeps Share Capital Unchanged in July 2026 and Meets Public-Float Requirement

Bulletin Express08-03

VISEN Pharmaceuticals (VISEN Pharma, 02561.HK) released its Monthly Return for Equity Issuer for the period ended 31 July 2026, showing no movement in authorised, issued or treasury shares during the month.

The company’s authorised share capital stood unchanged at 500.00 million ordinary shares with a par value of USD0.0001 each, equivalent to USD50,000 in aggregate.

Issued share capital (excluding treasury shares) remained at 113.75 million shares, supplemented by 0.17 million treasury shares, bringing total issued shares to 113.93 million. No new shares were issued, cancelled, or transferred in or out of treasury during July 2026.

VISEN Pharma confirmed that it continued to satisfy the Main Board’s minimum public-float requirement of at least 25% of issued shares held by the public as of month-end.

Under the Post-IPO Share Award Scheme approved on 16 November 2022, up to 2.40 million shares may be issued upon vesting of awards. Although 514,068 award shares were granted in July 2026, none were issued during the month.

No movements were recorded in respect of share options, warrants, convertibles, or other share-related agreements beyond the award scheme. The company further confirmed that all listing rule and regulatory compliance obligations related to any potential securities issuance have been met.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1130295885?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-03 17:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1130295885","market":"hk","top_or_hot":-1,"title":"VISEN Pharma Keeps Share Capital Unchanged in July 2026 and Meets Public-Float Requirement","media":"Bulletin Express","content":"<p>VISEN Pharmaceuticals (VISEN Pharma, 02561.HK) released its Monthly Return for Equity Issuer for the period ended 31 July 2026, showing no movement in authorised, issued or treasury shares during the month.</p>\n<p>The company’s authorised share capital stood unchanged at 500.00 million ordinary shares with a par value of USD0.0001 each, equivalent to USD50,000 in aggregate.</p>\n<p>Issued share capital (excluding treasury shares) remained at 113.75 million shares, supplemented by 0.17 million treasury shares, bringing total issued shares to 113.93 million. No new shares were issued, cancelled, or transferred in or out of treasury during July 2026.</p>\n<p>VISEN Pharma confirmed that it continued to satisfy the Main Board’s minimum public-float requirement of at least 25% of issued shares held by the public as of month-end.</p>\n<p>Under the Post-IPO Share Award Scheme approved on 16 November 2022, up to 2.40 million shares may be issued upon vesting of awards. Although 514,068 award shares were granted in July 2026, none were issued during the month.</p>\n<p>No movements were recorded in respect of share options, warrants, convertibles, or other share-related agreements beyond the award scheme. The company further confirmed that all listing rule and regulatory compliance obligations related to any potential securities issuance have been met.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>VISEN Pharma Keeps Share Capital Unchanged in July 2026 and Meets Public-Float Requirement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVISEN Pharma Keeps Share Capital Unchanged in July 2026 and Meets Public-Float Requirement\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-08-03 17:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>VISEN Pharmaceuticals (VISEN Pharma, 02561.HK) released its Monthly Return for Equity Issuer for the period ended 31 July 2026, showing no movement in authorised, issued or treasury shares during the month.</p>\n<p>The company’s authorised share capital stood unchanged at 500.00 million ordinary shares with a par value of USD0.0001 each, equivalent to USD50,000 in aggregate.</p>\n<p>Issued share capital (excluding treasury shares) remained at 113.75 million shares, supplemented by 0.17 million treasury shares, bringing total issued shares to 113.93 million. No new shares were issued, cancelled, or transferred in or out of treasury during July 2026.</p>\n<p>VISEN Pharma confirmed that it continued to satisfy the Main Board’s minimum public-float requirement of at least 25% of issued shares held by the public as of month-end.</p>\n<p>Under the Post-IPO Share Award Scheme approved on 16 November 2022, up to 2.40 million shares may be issued upon vesting of awards. Although 514,068 award shares were granted in July 2026, none were issued during the month.</p>\n<p>No movements were recorded in respect of share options, warrants, convertibles, or other share-related agreements beyond the award scheme. The company further confirmed that all listing rule and regulatory compliance obligations related to any potential securities issuance have been met.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02561","symbol_name":"维昇药业-B","start_time":0,"source_url":"","article_id":"1130295885","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1130295885","pubTimestamp":1785748157,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"VISEN Pharmaceuticals (VISEN Pharma, 02561.HK) released its Monthly Return for Equity Issuer for the period ended 31 July 2026, showing no movement in authorised, issued or treasury shares during the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02561":"维昇药业-B"},"translate_title":"VISEN Pharma 2026年7月股本保持不变，符合公开发行要求","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02561":1},"content_text":"VISEN Pharmaceuticals (VISEN Pharma, 02561.HK) released its Monthly Return for Equity Issuer for the period ended 31 July 2026, showing no movement in authorised, issued or treasury shares during the month.\nThe company’s authorised share capital stood unchanged at 500.00 million ordinary shares with a par value of USD0.0001 each, equivalent to USD50,000 in aggregate.\nIssued share capital (excluding treasury shares) remained at 113.75 million shares, supplemented by 0.17 million treasury shares, bringing total issued shares to 113.93 million. No new shares were issued, cancelled, or transferred in or out of treasury during July 2026.\nVISEN Pharma confirmed that it continued to satisfy the Main Board’s minimum public-float requirement of at least 25% of issued shares held by the public as of month-end.\nUnder the Post-IPO Share Award Scheme approved on 16 November 2022, up to 2.40 million shares may be issued upon vesting of awards. Although 514,068 award shares were granted in July 2026, none were issued during the month.\nNo movements were recorded in respect of share options, warrants, convertibles, or other share-related agreements beyond the award scheme. The company further confirmed that all listing rule and regulatory compliance obligations related to any potential securities issuance have been met.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX,express","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1130295885","isCrawlerRequest":true}